All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
KYE Pharmaceuticals announces FIRDAPSE® (amifampridine phosphate), the first amifampridine product approved in Canada, is now widely available for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 16, 2020
Details:
Aequus has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. on tacrolimus immediate-release Tacrolimus IR to December 31st, 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Ruzurgi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Jacobus Pharmaceutical Company, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi® and management of its UnikAccess Patient Support Program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on the List of Medications- Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ), effective August 19, 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Catalyst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2020
Details:
Under the terms of the agreement, Catalyst will supply Firdapse® to KYE and KYE will be responsible for promotion, sales, advertisement, marketing, product importation and distribution.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
The allowed application, "Methods of Administering 3,4-Diaminopyridine", claims a method of treating a human patient diagnosed with a 3,4-DAP sensitive disease by administering 3,4-DAP to slow acetylating patients having certain mutations in each allele of the NAT2 gene.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
The marketing application submitted to Health Canada included safety and efficacy data from Catalyst’s two previously reported multi-national clinical trials evaluating Firdapse® for the treatment of patients with LEMS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
